Compliance with endocrine therapy among breast cancer survivors.

IF 1 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Danish medical journal Pub Date : 2024-11-20 DOI:10.61409/A05240316

Emma Marie Torpe, Tobias Berg, Maj-Britt Jensen, Bent Ejlertsen

{"title":"Compliance with endocrine therapy among breast cancer survivors.","authors":"Emma Marie Torpe, Tobias Berg, Maj-Britt Jensen, Bent Ejlertsen","doi":"10.61409/A05240316","DOIUrl":null,"url":null,"abstract":"Introduction: Most postmenopausal women with early-stage oestrogen receptor-positive breast cancer are allocated to five years of endocrine therapy. This treatment is not without adverse effects, which may lead to treatment discontinuation. This study aimed to assess compliance with endocrine therapy among postmenopausal women with early-stage oestrogen receptor-positive breast cancer and examine its association with disease-free survival.Methods: This study retrospectively identified a cohort of 360 postmenopausal women diagnosed in the period from 1 January 2015 to 31 December 2017 at Rigshospitalet, Copenhagen, Denmark, with early-stage oestrogen receptor-positive breast cancer in the clinical database of the Danish Breast Cancer Group. Kaplan-Meier was used to estimate compliance and disease-free survival.Results: A total of 346 patients receiving endocrine therapy were included, 240 were compliant, and 106 were non-compliant. The median follow-up was 6.5 years (95% confidence interval (CI): 6.4-6.7 years). The compliance at 4.5 years was 68.8% (95% CI: 64.1-74.0%). Disease-free survival was significantly higher for the compliant group (adjusted HR = 2.29; 95% CI: 1.34-3.91).Conclusions: We found a low compliance at 4.5 years and most discontinuations were due to adverse effects. The study provides evidence that low compliance with endocrine therapy had a negative impact on disease-free survival.Funding: The study was funded by the Danish Cancer Society.Trial registration: The study was approved by the research overview of the Capital of Denmark and the Center for Health.","PeriodicalId":11119,"journal":{"name":"Danish medical journal","volume":"71 12","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Danish medical journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.61409/A05240316","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Most postmenopausal women with early-stage oestrogen receptor-positive breast cancer are allocated to five years of endocrine therapy. This treatment is not without adverse effects, which may lead to treatment discontinuation. This study aimed to assess compliance with endocrine therapy among postmenopausal women with early-stage oestrogen receptor-positive breast cancer and examine its association with disease-free survival.

Methods: This study retrospectively identified a cohort of 360 postmenopausal women diagnosed in the period from 1 January 2015 to 31 December 2017 at Rigshospitalet, Copenhagen, Denmark, with early-stage oestrogen receptor-positive breast cancer in the clinical database of the Danish Breast Cancer Group. Kaplan-Meier was used to estimate compliance and disease-free survival.

Results: A total of 346 patients receiving endocrine therapy were included, 240 were compliant, and 106 were non-compliant. The median follow-up was 6.5 years (95% confidence interval (CI): 6.4-6.7 years). The compliance at 4.5 years was 68.8% (95% CI: 64.1-74.0%). Disease-free survival was significantly higher for the compliant group (adjusted HR = 2.29; 95% CI: 1.34-3.91).

Conclusions: We found a low compliance at 4.5 years and most discontinuations were due to adverse effects. The study provides evidence that low compliance with endocrine therapy had a negative impact on disease-free survival.

Funding: The study was funded by the Danish Cancer Society.

Trial registration: The study was approved by the research overview of the Capital of Denmark and the Center for Health.

查看原文本刊更多论文

乳腺癌幸存者对内分泌治疗的依从性

大多数绝经后早期雌激素受体阳性乳腺癌妇女被分配到5年的内分泌治疗。这种治疗并非没有副作用，可能导致停止治疗。本研究旨在评估绝经后早期雌激素受体阳性乳腺癌患者对内分泌治疗的依从性，并探讨其与无病生存率的关系。方法：本研究回顾性地确定了一组360名绝经后妇女，这些妇女于2015年1月1日至2017年12月31日在丹麦哥本哈根的Rigshospitalet诊断为早期雌激素受体阳性乳腺癌，来自丹麦乳腺癌组的临床数据库。Kaplan-Meier法用于评估依从性和无病生存期。结果：共纳入346例接受内分泌治疗的患者，依从性240例，不依从性106例。中位随访时间为6.5年（95%可信区间（CI）： 6.4-6.7年）。4.5年时的依从性为68.8% （95% CI: 64.1-74.0%）。依从组的无病生存率显著高于依从组(调整后HR = 2.29；95% ci: 1.34-3.91)。结论：我们发现4.5年的依从性较低，大多数停药是由于不良反应。该研究提供了证据，证明低依从性内分泌治疗对无病生存有负面影响。资助：该研究由丹麦癌症协会资助。试验注册：该研究已获得丹麦首都和卫生中心的研究综述批准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Danish medical journal MEDICINE, GENERAL & INTERNAL-

CiteScore

2.30

自引率

6.20%

发文量

审稿时长

3-8 weeks

期刊介绍： The Danish Medical Journal (DMJ) is a general medical journal. The journal publish original research in English – conducted in or in relation to the Danish health-care system. When writing for the Danish Medical Journal please remember target audience which is the general reader. This means that the research area should be relevant to many readers and the paper should be presented in a way that most readers will understand the content. DMJ will publish the following articles: • Original articles • Protocol articles from large randomized clinical trials • Systematic reviews and meta-analyses • PhD theses from Danish faculties of health sciences • DMSc theses from Danish faculties of health sciences.